Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Innate Biologics LLC has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. Both actions are assigned to 1 distinct examiner, CRUM, MARY ABOU NADER, within 1 distinct art unit. This indicates a high level of concentration for the company's pending matters. The focus on a single examiner and art unit suggests a streamlined prosecution process for these biotechnology filings. This concentration allows for a consistent dialogue with the USPTO regarding the company's core technology.
CRUM, MARY ABOU NADER is the busiest examiner with 2 pending actions. This accounts for all 2 of the company's pending office actions. The use of 1 distinct art unit further confirms that the current prosecution is centralized under a single examiner and unit. Practitioners can expect a consistent examination experience across both pending actions, as they are being handled by the same individual within the Biotechnology & Pharmaceuticals sector. This centralized approach simplifies the management of the company's current pending workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRUM, MARY ABOU NADER | 2 | 40.4% | +65.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19305204 | IMMUNOMODULATORY COMPOSITIONS AND METHODS | CRUM, MARY ABOU NADER | 69d |
| 17514472 | IMMUNOMODULATORY COMPOSITIONS AND METHODS | CRUM, MARY ABOU NADER | — |
| Art Unit | Apps |
|---|---|
| 1657 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19305204 | IMMUNOMODULATORY COMPOSITIONS AND METHODS | CRUM, MARY ABOU NADER | 1657 | §112DP | Final Rejection | 69d | Pending | Aug 20, 2025 |
| 17514472 | IMMUNOMODULATORY COMPOSITIONS AND METHODS | CRUM, MARY ABOU NADER | 1657 | §103§112DP | Non-Final OA | — | Pending | Oct 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial